Efficacy of GONB in Patients of Migraine

Pain Medicine Department50 enrolled

Overview

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Chronic Migraine Headache

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients between 18 to 60 years * diagnosed case of migraine Exclusion Criteria: * Patients with known allergies to local anaesthetics * pregnancy * history of cranial or cervical surgery * head injury * headaches secondary to medication overuse * patients with uncontrolled systemic disease like blood pressure, diabetes mellitus * hypo or hyperthyroidism * patient who had already received GONB or botulinum toxin type A therapy within last 6 months * major psychiatric disorder * history of chronic pain syndromes

Outcomes

Primary Outcomes

Analgesic efficacy

Change in Pain score assessed on Numeric Rating Scale (NRS) which ranges from 0 to 10. 0 is no pain and 10 is maximum pain.

Time frame: 12 weeks

Secondary Outcomes

Headache days

Number of headache days over the course of study period.